0

524314

GUJTERC

img img img img
No Data Available

GUJARAT TERCE LABORATORIES LTD Share Price Update

As of the latest trading session, GUJARAT TERCE LABORATORIES LTD is trading at ₹37, up by ₹1.02 or 2.83% from its previous close. The stock has moved between ₹35.00 and ₹37.90 today. Over the past year, the stock has delivered a return of -38.00%. In the last month, it has returned 11.91%.

Investment Returns

Over 1 Month 11.91% Over 3 Months -15.10% Over 6 Months -21.74% Over 1 Year -38.00%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

GUJARAT TERCE LABORATORIES LTD fundamentals


  • Market cap (Cr) [-]
  • P/E Ratio (TTM) [-]
  • Beta [-]
  • Book Value / share [-]
  • Return on equity [-]%
  • EPS (TTM) [-]
  • Dividend yield [-]%
  • Net profit/quarter (Cr) [-]
info icon alternate text
  • Market cap (Cr) 28.80
  • P/E Ratio (TTM) -22.07
  • Beta 0.60
  • Book Value / share 11.40
  • Return on equity 0.00%
  • EPS (TTM) 0.00
  • Dividend yield [-]%
  • Net profit/quarter (Cr) 0.76
info icon alternate text

GUJARAT TERCE LABORATORIES LTD Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars DEC 2025 (Values in Cr)
Revenue 12.29
Operating Expense 11.29
Net Profit 0.76
Net Profit Margin (%) 6.18
Earnings Per Share (EPS) 0.95
EBITDA 1.27
Effective Tax Rate (%) 32.74
Particulars SEP 2025 (Values in Cr)
Revenue 12.93
Operating Expense 11.20
Net Profit 1.40
Net Profit Margin (%) 10.82
Earnings Per Share (EPS) 1.89
EBITDA 1.95
Effective Tax Rate (%) 21.34
Particulars JUN 2025 (Values in Cr)
Revenue 10.85
Operating Expense 11.02
Net Profit -0.04
Net Profit Margin (%) -0.36
Earnings Per Share (EPS) -0.06
EBITDA 0.08
Effective Tax Rate (%) 42.85
Particulars MAR 2025 (Values in Cr)
Revenue 12.32
Operating Expense 11.44
Net Profit -3.39
Net Profit Margin (%) -27.51
Earnings Per Share (EPS) -4.57
EBITDA 1.14
Effective Tax Rate (%) 449.48
Particulars DEC 2024 (Values in Cr)
Revenue 12.68
Operating Expense 11.77
Net Profit 1.01
Net Profit Margin (%) 7.96
Earnings Per Share (EPS) 1.36
EBITDA 1.16
Effective Tax Rate (%) -3.06
Particulars MAR 2025 (Values in Cr)
Revenue 50.20
Operating Expense 47.12
Net Profit -0.98
Net Profit Margin (%) -1.95
Earnings Per Share (EPS) -1.31
EBITDA 4.19
Effective Tax Rate (%) 128.90
Particulars MAR 2024 (Values in Cr)
Revenue 47.97
Operating Expense 47.76
Net Profit 0.24
Net Profit Margin (%) 0.50
Earnings Per Share (EPS) 0.33
EBITDA 1.59
Effective Tax Rate (%) 55.55
Particulars MAR 2023 (Values in Cr)
Revenue 46.78
Operating Expense 50.03
Net Profit -1.67
Net Profit Margin (%) -3.56
Earnings Per Share (EPS) -2.25
EBITDA -1.81
Effective Tax Rate (%) 42.21
Particulars MAR 2022 (Values in Cr)
Revenue 40.13
Operating Expense 39.69
Net Profit 0.87
Net Profit Margin (%) 2.16
Earnings Per Share (EPS) 1.18
EBITDA 1.43
Effective Tax Rate (%) -17.33
Particulars MAR 2021 (Values in Cr)
Revenue 25.18
Operating Expense 28.51
Net Profit -2.52
Net Profit Margin (%) -10.00
Earnings Per Share (EPS) -3.40
EBITDA -1.95
Effective Tax Rate (%) 0.39
Particulars MAR 2025 (Values in Cr)
Book Value / Share 8.26
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.35
EBITDA Margin 8.37
Particulars MAR 2024 (Values in Cr)
Book Value / Share 9.58
ROE % 2.96
ROCE % 7.17
Total Debt to Total Equity 0.80
EBITDA Margin 3.31
Particulars MAR 2023 (Values in Cr)
Book Value / Share 9.25
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.91
EBITDA Margin -3.87
Particulars MAR 2022 (Values in Cr)
Book Value / Share 11.50
ROE % 10.24
ROCE % 6.74
Total Debt to Total Equity 0.70
EBITDA Margin 3.54
Particulars MAR 2021 (Values in Cr)
Book Value / Share 10.33
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.39
EBITDA Margin -7.82
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 0.77
Total Assets 22.82
Total Liabilities 22.82
Total Equity 6.47
Share Outstanding 0
Price to Book Ratio 7.40
Return on Assets (%) -4.28
Return on Capital (%) -13.19
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.09
Total Assets 23.27
Total Liabilities 23.27
Total Equity 7.10
Share Outstanding 0
Price to Book Ratio 5.53
Return on Assets (%) 1.04
Return on Capital (%) 2.22
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 2.02
Total Assets 28.52
Total Liabilities 28.52
Total Equity 6.86
Share Outstanding 0
Price to Book Ratio 1.80
Return on Assets (%) -5.85
Return on Capital (%) -11.83
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 1.50
Total Assets 27.39
Total Liabilities 27.39
Total Equity 8.53
Share Outstanding 0
Price to Book Ratio 2.27
Return on Assets (%) 3.18
Return on Capital (%) 5.74
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.28
Total Assets 21.87
Total Liabilities 21.87
Total Equity 7.66
Share Outstanding 0
Price to Book Ratio 0.67
Return on Assets (%) -11.52
Return on Capital (%) -20.33
Particulars MAR 2025 (Values in Cr)
Net Income 3.39
Cash from Operations 3.14
Cash from Investing 0.45
Cash from Financing -2.82
Net change in Cash 0.68
Free Cash Flow 3.14
Particulars MAR 2024 (Values in Cr)
Net Income 0.54
Cash from Operations 2.59
Cash from Investing -0.45
Cash from Financing -4.08
Net change in Cash -1.93
Free Cash Flow 2.67
Particulars MAR 2023 (Values in Cr)
Net Income -2.89
Cash from Operations 0.06
Cash from Investing 0.61
Cash from Financing -0.12
Net change in Cash 0.52
Free Cash Flow 0.12
Particulars MAR 2022 (Values in Cr)
Net Income 0.74
Cash from Operations -0.34
Cash from Investing -0.86
Cash from Financing 1.53
Net change in Cash 0.22
Free Cash Flow 1.77
Particulars MAR 2021 (Values in Cr)
Net Income -2.52
Cash from Operations -0.01
Cash from Investing -0.42
Cash from Financing 1.83
Net change in Cash 1.24
Free Cash Flow 0.48
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 31.79 13.76 1.65 243.62 23.12 40.44
BLISS GVS PHARMA LTD 271.90 25.99 2.54 2876.40 105.05 280.20
CIPLA LTD 1362.85 23.15 3.34 110088.66 1165.55 1672.20
FERMENTA BIOTECH LIMITED 300.95 10.01 2.26 885.73 252.15 399.00
GLAXOSMITHKLINE PHARMACEUTICAL 2478.95 41.75 24.59 41994.91 2218.00 3515.95
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 31.79 30.57 4.43 243.62 23.12 40.44
AMRUTAJAN HEALTH LTD 558.60 27.93 4.72 1614.95 490.00 789.95
ASTRAZENECA PHARMA INDIA LTD. 8535.30 102.58 26.70 21338.25 7630.00 10653.05
BLISS GVS PHARMA LTD 271.90 37.04 2.60 2876.40 105.05 280.20

GUJARAT TERCE LABORATORIES LTD shareholding pattern

Holding
59.97%
40.02%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

GUJARAT TERCE LABORATORIES LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
37.00 2.83 redarrow
red-green-graph indicator
10 Bearish
6 Bullish
  • 5 Days 36.90
  • 26 Days 36.70
  • 10 Days 37.10
  • 50 Days 37.60
  • 12 Days 37.00
  • 100 Days 40.00
  • 20 Days 36.70
  • 200 Days 44.10
36.13 PIVOT
First Support 34.41 First Resistance 37.71 Second Support 32.83 Second Resistance 39.43 Third Support 31.11 Third Resistance 41.01
RSI 46.99 ADX 9.60 MACD 0.25 Williams % R -70.41 Commodity Channel Index (CCI) -6.26
Date 2026-05-07 Week 2009.00 Same Day 5820.00 Month 7676.00
1 Year 0.60 3 Year 0.20
Over 1 Month
11.91% down
Over 1 Year
-38.00% down
Over 3 Months
-15.10% down
Over 3 Years
21.09% down
Over 6 Months
-21.74% down
Over 5 Years
28.87% down

GUJARAT TERCE LABORATORIES LTD Corporate Actions

Top Gainers

Top Losers

GUJARAT TERCE LABORATORIES LTD Share Price

Gujarat Terce Laboratories Limited, incorporated in 1985, is a trusted manufacturer of high quality medication at affordable rates for the common man. Company specialise in producing oral solid dosages, including tablets and capsules, that address various therapeutic needs.
Headquartered in Ahmedabad, Gujarat, Terce offers an extensive portfolio featuring over 125 products and more than 64 well-established brands.

By 1986, Terce had established its presence in Gujarat and Rajasthan with a firm footing. In 1992, the management raised public equity to give concrete shape and listed the Company on Bombay Stock Exchange. In same year, Company established extensive manufacturing facility at Chhatral in Gandhinagar, Gujarat. As India heralded new leaps in the pharma sector to become a global force to reckon with by 2005, the Company closely followed the narrative with ferocious growth expanding presence in the domestic and international market.

The Company offers products in the form of tablets, capsules, syrups, and injections. The installed capacity of the Company is 270 million tablets and 108 million capsules per annum. It focuses on formulation improvements, new product development, and research to identify gaps in existing treatment options.

The Company otherwise or hence maintains strict and controlled environment for manufacturing and adheres to Good Manufacturing Practices and Good Laboratory Practices to assure highest level of patient safety and outcome efficacy. It has well-defined Total Quality Management System in place to continuously optimize products and processes. Each process is thoroughly monitored and data is collected for analysis which helps in planning corrective and preventive strategies for quality control.

To serve the needs of patients and healthcare professionals, Company focus on early and rapid detection of diseases. Their team of scientists is supported by doctors, patients and marketing team in identifying pressing needs and developing solutions. It has capabilities of innovation across generic drugs to complex formulations, biosimilars and new molecular entity.

Parent organization Indian Private
NSE symbol [-]
Founded 1985
stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Gujarat Terce Laboratories Ltd?

Answer Field

Gujarat Terce Laboratories Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 37.00 as on May 08 2026 03:30 PM.

What is the Market Cap of Gujarat Terce Laboratories Ltd Share?

Answer Field

The market cap of Gujarat Terce Laboratories Ltd for NSE ₹ 0.00 & for BSE ₹ 28.80 as on May 08 2026 03:30 PM.

What is the 52 Week High and Low of Gujarat Terce Laboratories Ltd?

Answer Field

The 52 Week High and Low of Gujarat Terce Laboratories Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 68.40 and ₹ 29.00.

What is 1 year return for Gujarat Terce Laboratories Ltd?

Answer Field

The 1 year returns on the stock has been -38.00%.

What is the P/E Ratio of Gujarat Terce Laboratories Ltd Share?

Answer Field

As on May 08 2026 03:30 PM the price-to-earnings (PE) ratio for Gujarat Terce Laboratories Ltd share is -22.07.

What is the PB ratio of Gujarat Terce Laboratories Ltd Share?

Answer Field

As on May 08 2026 03:30 PM, the price-to-book (PB) ratio for Gujarat Terce Laboratories Ltd share is 11.40.

How to Buy Gujarat Terce Laboratories Ltd Share?

Answer Field

You can trade in Gujarat Terce Laboratories Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Gujarat Terce Laboratories Ltd Share on Bajaj Broking App?

Answer Field

To buy Gujarat Terce Laboratories Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Gujarat Terce Laboratories Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|